Bibliography
- KONTOGHIORGHES GJ, ERACLEOUS E, ECONOMIDES CH, KOLNAGOU A: Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr. Med. Chem. (2005) 12:2663-2681.
- KONTOGHIORGHES GJ, NEOKLEOUS K, KOLNAGOU A: Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Drug Saf. (2003) 26:553-584.
- WORLD HEALTH ORGANISATION: Community control of hereditary anaemias. WHO Bull. (1983) 61:63-80.
- KYRIACOU K, MICHAELIDES Y, SENKUS R et al.: Ultrastructural pathology of the heart in patients with β-thalassaemia major. Ultastructural Pathology (2000) 24:75-81.
- ANDERSON LJ, WESTWOOD MA, HOLDEN S et al.: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. (2004) 127:348-355.
- NIELSEN P, FISCHER R, ENGELHARDT R et al.: Liver iron stores in patients with secondary haemochromatosis under iron chelation therapy with deferoxamine or deferiprone. Br. J. Haematol. (1995) 91:827-833
- MODELL B, BERDOUKAS V: The clinical approach to thalassaemia. Grune and Stratton, London, UK (1984).
- KEBERLE H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci. (1964) 119:758-768.
- MODELL B, KHAN M, DARLISON M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet (2000) 355:2051-2052.
- KONTOGHIORGHES GJ, ALDOURI MA, HOFFBRAND AV et al.: Effective chelation of iron in β-thalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Br. Med. J. (1987) 295:1509-1512.
- ANDERSON LJ, WONKE B, PRESCOTT E et al.: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (2002) 360:516-520.
- KONTOGHIORGHES GJ, SHEPPARD L: Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorg. Chim. Acta (1987) 136:L11-L12.
- ORIGA R, BINA P, AGUS A et al.: Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. (2005) 90:1309-1314.
- NISBET-BROWN E, OLIVIERI NF, GIARDINA PJ et al.: Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 361:1597-1602.
- CAPPELINI MD: Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Prac. Res. Clin. Haematol. (2005) 18:289-298.
- MARQUIS J, DAGHER R, BREE M et al.: Pharmacokinetic of GT56-252, a novel orally available iron chelator in rat, dog and monkey. Biomarkers Environment (2003) 6:7-9.
- DONOVAN JM, PALMER PA, PLONE MA, WONKE B: The safety and pharmacokinetics of GT56-252, a novel orally available iron chelator. Eur. J. Clin. Invest. (2004) 34(Suppl. I):39.
- KONTOGHIORGHES GJ, BARR J, NORTEYT P, SHEPPARD L: Selection of a new generation of orally active α-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Am. J. Haematol. (1993) 42:340-349.
- HARMATZ P, GRADY RW, VICHINSKY E et al.: Phase Ib study of the safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02(CHF5140, GS460) in iron-loaded patients. Blood (2003) 102:423.
- DRAGSTEN PR, HALLAWAY PE, HANSON GJ et al.: First human studies with a high-molecular-weight iron chelator. J. Lab. Clin. Med. (2000) 135:57-65.